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Introduction: There are many proven treatments
(psychotherapy, pharmacotherapy or their
combination) for the treatment of depression. Although
there is growing evidence for the effectiveness of
combination treatment (psychotherapy +
pharmacotherapy) over pharmacotherapy alone,
psychotherapy alone or psychotherapy plus pill
placebo, for depression, little is known about which
specific groups of patients may respond best to
combined treatment versus monotherapy. Conventional
meta-analyses techniques have limitations when tasked
with examining whether specific individual
characteristics moderate the effect of treatment on
depression. Therefore, this protocol outlines an
individual patient data (IPD) meta-analysis to explore
which patients, with which clinical characteristics, have
better outcomes in combined treatment compared with
psychotherapy (alone or with pill placebo),
pharmacotherapy and pill placebo.
Methods and Analysis: Study searches are
completed using an established database of
randomised controlled trials (RCTs) on the
psychological treatment of adult depression that has
previously been reported. Searches were conducted in
PubMed, PsycInfo, Embase and the Cochrane Central
Register of Controlled Trials. RCTs comparing
combination treatment (psychotherapy +
pharmacotherapy) with psychotherapy (with or without
pill placebo), pharmacotherapy or pill placebo for the
treatment of adult depression will be included. Study
authors of eligible trials will be contacted and asked to
contribute IPD. Conventional meta-analysis techniques
will be used to examine differences between studies
that have contributed data and those that did not.
Then, IPD will be harmonised and analysis using
multilevel regression will be conducted to examine
effect moderators of treatment outcomes.
Dissemination: Study results outlined above will be
published in peer-reviewed journals. Study results will
contribute to better understanding whether certain
patients respond best to combined treatment or other
depression treatments and provide new information on
moderators of treatment outcome that can be used by
patients, clinicians and researchers.
Trial registration number: CRD42016039028.
INTRODUCTION
There are many evidence-based treatments
for depression such as various psychothera-
pies like cognitive behaviour therapy (CBT),
behavioural activation (BA), interpersonal
therapy (IPT), problem-solving therapy
(PST) and psychodynamic therapy1–5 and
there are various classes of antidepressant
medications such as the selective serotonin
reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors (SNRIs),
Strengths and limitations of this study
▪ This is the first individual patient data (IPD)
meta-analysis of combined treatment for depres-
sion versus pharmacotherapy alone, psychother-
apy alone or psychotherapy plus pill placebo for
depression.
▪ Using IPD meta-analysis methods will allow for
examination of individual patient’s clinical and
demographic characteristics as moderators
between combined treatment and comparator
treatments for depression by maximising statis-
tical power while protecting against ecological
fallacies that present problems when examining
aggregate data using conventional meta-analysis
techniques.
▪ This study can contribute important information
towards identifying factors that affect response
to varying depression treatments.
▪ However, the IPDMA is limited to only examining
factors that are reported similarly across all of
the included individual studies.
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tricyclic antidepressants (TCAs) and monoamine
oxidase inhibitors (MAOIs).6 Many of these treatments
have been found to be as effective as monotherapy and
to be comparable with one another.7 Researchers and
treatment guidelines generally agree that either type of
monotherapy may be useful in the treatment of mild to
moderate depression; however, treatment guidelines
suggest a combination of psychotherapy and pharmaco-
therapy for the treatment of more moderate to severe
depression.8–10 In addition, there is growing evidence
from randomised controlled trials (RCTs) and conven-
tional meta-analyses that combination treatment is more
effective for the acute phase treatment of depression
than psychotherapy alone,11 12 pharmacotherapy alone13
and psychotherapy plus pill placebo.14
Although much is known about how well depression
treatments work on average, less is known about how
these treatments work at the level of the individual
patient. For instance, different treatments may be com-
parably effective for the average patient, yet some
patients may improve more on a combination of treat-
ments than a certain monotherapy.15 Factors that can
predict differential response between two treatments are
known as effect modifiers or moderators.16 Similarly,
many patients respond as well on a specific monother-
apy as they do in combined treatment, therefore, using
combined treatment for these patients would waste valu-
able economic resources given that combined treat-
ments are much more costly to provide. Knowing under
which circumstances an individual with a certain charac-
teristic would have a superior response to a monother-
apy or to combination treatment would have important
implications for clinical practice and subsequent
research (specific response points to specific causal
mechanisms), and would add to the growing body of evi-
dence moving towards what is frequently called persona-
lised medicine.17–19
In order to determine which patients respond best to
which treatments, it is necessary to examine individual
baseline clinical (depression severity, psychopathological
comorbidities, depression chronicity, previous exposure
to treatment, etc) and demographic characteristics more
closely. Few RCTs have examined these individual
characteristics as moderators of differential response in
depression treatment outcomes between combined treat-
ment versus monotherapy, control conditions or psycho-
therapy plus pill placebo. In those trials that have
examined individual characteristics as moderators of dif-
ferential response between combination and comparison
treatments, baseline depression severity was the most
commonly examined variable with mixed results. One
recent trial found that combined therapy was worse than
pharmacotherapy alone for those with severe depres-
sion,20 whereas another found that patients with severe
depression had an increased rate of recovery in combi-
nation treatment versus pharmacotherapy alone.21 In
addition, a meta-analysis that examined studies including
less severe patients and studies incorporating more
severe patients found greater remission rates in com-
bined treatment compared with psychotherapy alone for
those with severe or chronic depression, but no differ-
ence in those with mild depression.12 Demographic and
other clinical variables have gone largely unassessed as
moderators between combined treatment and psycho-
therapy, pharmacotherapy or pill placebo monotherapy
or psychotherapy plus pill placebo combination treat-
ment in RCTs, but have been examined more thor-
oughly in RCTs of psychotherapy and pharmacotherapy
with some success.15 22–26 However, the problem with
this method is that these trials often have smaller sample
sizes and limited statistical power to detect significance
of these variables without encountering a type I or type
II error. To the best of our knowledge, no studies of
combination treatment versus pill placebo alone or psy-
chotherapy plus pill placebo have documented any mod-
erating variables.
Conventional meta-analysis techniques are commonly
used to aggregate outcome data of RCTs of depression.
However, these techniques often cannot be used appro-
priately when examining moderation since data may not
be reported in published papers, or may be reported dif-
ferently across trials, which prevents aggregation. When
aggregation is possible in meta-analysis, it is often by use
of subgroup analysis and this can also limit statistical
power and accuracy of analysis since it leads to a loss of
degrees of freedom and variability in the moderator of
interest that may lead to ecological fallacies. Therefore,
conducting an individual patient data (IPD)
meta-analysis, by collecting and aggregating the raw IPD
from RCTs is necessary in order to better understand
the predictive nature of individual characteristics on the
difference between combination treatment and psycho-
therapy or pharmacotherapy monotherapy, pill placebo
or psychotherapy plus pill placebo for the treatment of
depression.
IPD meta-analysis techniques have been used with
some frequency in medicine,27 but are newer in the
field of clinical psychology and psychiatry. IPD methods
can offer several advantages in summarising existing evi-
dence from individual trials. As the field moves towards
personalised medicine, being able to select the best
treatment for groups of patients with certain character-
istics, IPD methods can be a useful tool for examining
moderators of varying outcomes with sufficient power.
Although it is possible that IPD meta-analysis will not
uncover significant moderators of interest even with
additional power, this would be an equally important
finding for the field of personalised medicine.
IPD meta-analyses also present many challenges.
These methods are more time and resource intensive
than conventional meta-analyses. Using these methods is
dependent on accessing raw data from researchers and
it involves making complex decisions on data to ensure
accuracy of outcomes. IPD methods are described in
detail in this protocol, which outlines the design of an
IPD meta-analysis of combined treatment compared
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with psychotherapy (with or without pill placebo),
pharmacotherapy or pill placebo for adult depression.
The main objective of this meta-analysis is to determine
which patients respond better to combined treatment
(psychotherapy + pharmacotherapy) compared with
monotherapies (pharmacotherapy, psychotherapy or pill




This IPD meta-analysis involves selecting eligible
research, collecting relevant data and subsequently,
using two separate meta-analytic approaches for data
analysis. First a systematic review to identify eligible
papers will be performed, studies will be selected and
study authors will be invited to contribute data. A con-
ventional meta-analysis will then be performed to test
for differences between studies included in the IPD
meta-analysis and those that could not provide data.
Individual data will be aggregated and previously
selected moderator variables will be analysed using a
multilevel model approach.
Systematic review to identify eligible papers
Eligibility criteria
Types of studies
This study will include published RCTs. Non-randomised
studies will not be included.
Type of participants
Participants of all genders and ethnicities who are 18 years
of age or older and who have been diagnosed with a
depressive disorder established by a standardised diagnos-
tic interview will be included in this systematic review and
meta-analysis. Studies that include populations with
comorbid general medical disorders or other psychiatric
disorders are not excluded as long as these comorbid dis-
orders are not the primary focus of the study.
Types of interventions
RCTs comparing combination treatment (psychother-
apy + pharmacotherapy) with psychotherapy (with or
without pill placebo), pharmacotherapy or pill
placebo for the treatment of adult depression will be
included. Psychotherapeutic interventions are
required to be a manualised form of psychotherapy in
which there is verbal communication between a ther-
apist and a patient, or where a psychological treat-
ment was written in a systematic format for a patient
to follow (in a book or on the internet) with some
support from a therapist.28 These will include the
major forms of psychotherapy such as CBT, IPT, PST,
BA, psychodynamic psychotherapy and others.
Pharmacotherapies will include antidepressant treat-
ment such as the SSRIs, SNRIs, TCAs and MAOIs,
among others.
Comparison treatments
Eligible comparison treatments will be (1) a psychother-
apy as indicated above, (2) an antidepressant pharmaco-
therapy as indicated above, (3) pill placebo or (4) a
combination of psychotherapy and pill placebo.
Types of outcome measures
Treatment efficacy will be measured by standardised
depression outcome measures such as the Beck
Depression Inventory (BDI);29 Hamilton Depression
Rating Scale (HAM-D);30 Montgomery-Asberg Depression
Rating Scale (MADRS)31 or other validated depression
measures. Preference will be given to measures listed as
primary outcome measures in the protocols. If two
primary outcome measures are used, preference will be
given to blinded assessments (clinician-interviewed over
self-report measures). If the type of outcome measures
used varies between studies, these measures will be trans-
formed into standardised z-scores to retain their properties
as continuous measures and also dichotomised to reflect
common clinical criteria such as response (a 50% reduc-
tion in symptoms at post-treatment) and remission
(maximum absolute scores reflecting normalisation).
They also will be dichotomised to reflect extreme response
and non-response/deterioration.32
Types of predictor/moderator variables
Published papers will be examined to determine valid pre-
dictors reported across studies. This project will focus on
clinical and demographic moderators of treatment out-
comes including correlates of depression severity.
Treatment guidelines recommend combined treatment
for patients with severe depression, thus suggesting that
there is a differential effect of treatment (combined vs
monotherapy) as a function of depression severity. In add-
ition, each of the particular moderator variables selected
has been examined in previous RCTs and has been found
to predict or moderate treatment outcomes in depression.
The clinical predictors that will be examined in this study
are: baseline depression severity25 33 34 measured on the
measures outlined above, having a comorbid mental
health diagnosis,15 23 anxiety symptoms,23 number of pre-
vious episodes (recurrence)26 35 length of current episode
(chronicity),17 global assessment of functioning (GAF)24
and previous exposure to depression treatments.15
Demographic moderators that will be examined in this
study are: marital status,15 22 36 employment,15 22
education26 and age.17 Other baseline demographic
characteristics will be gathered in order to adjust the ana-
lysis for these baseline characteristics. In addition, previous
literature has found that social adjustment24 predicted out-
comes, and thus will be included when available. It is
expected that not all studies assessed will be able to con-
tribute all variables, and thus, indices will be selected
when they uniquely examine a clinical correlate of interest
(ie, are not similar to another variable included) and
when a majority of studies have provided this particular
data.
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Timing of outcome assessments
All acute phase (postintervention) outcomes (between 5
and 36 weeks) will be included despite potential variabil-
ity in timeframes. If timing of interventions varies
extremely, sensitivity analyses examining the effect of
length of treatment on outcomes will be conducted. In
addition, length of treatment will be included as a
control variable in regression analyses. Long-term post-
treatment follow-ups will also be included if available
and separate analysis will be conducted on the acute
phase versus extended follow-ups.
Search methods for identification of studies
Study searches will be completed using an established
database of RCTs on the psychological treatment of
adult depression. This database has been described pre-
viously28 and used in a series of earlier published
meta-analyses.37 Comprehensive literature searches were
conducted (from 1966 to January 2015) to develop the
database that is updated every year in January. These
searches identified 16 365 abstracts to be examined from
Pubmed, Psychinfo, Embase and the Cochrane Central
Register of Controlled Trials. Abstracts and articles that
were pulled examined psychological treatments for
depression in general. In addition, the authors searched
previous meta-analyses of treatments for depression to
be sure that no randomised trials were missed in the
selection of papers. From the 16 407 abstracts (12 196
after the removal of duplicates), we retrieved 1885 full-
text papers of RCTs on treatments for depression for
possible inclusion in the database. Thus far, RCTs for
depression have been included in the database. These
papers were then screened for inclusion in this
meta-analysis.
Quality assessment
Study quality will be assessed by using six criteria from
the Cochrane Collaboration’s ‘risk of bias’ tool.38
Possible risks of bias assessed by this tool include
adequate generation of randomisation sequence, con-
cealment of treatment allocation, blinding of assessors,
use of appropriate methods for addressing missing data
(this was denoted as positive when analysis was com-
pleted on the intention-to-treat sample, meaning that all
randomised patients were included in the analysis),
selective outcome reporting and other sources of bias.
Only data from the published papers will be used to
determine the risk of bias so as to be consistent across
all studies that share data and those who cannot share
data. Two independent researchers conduct this quality
assessment.
Collecting and aggregating IPD
Inviting authors
All first authors of the identified included studies will be
contacted via email with a letter of invitation outlining
the project goals and asking if they would be willing to
collaborate by sharing the specific raw data from their
eligible trial. If an author does not respond after
1 month, a second attempt to contact them via email or
post will be made. If the second contact fails, another
author of the study will be contacted and invited to par-
ticipate. A second attempt to contact this author will
follow in another month if no response is received and
so forth until a maximum of three authors are con-
tacted. Study data will be considered unavailable in the
event that no study authors have responded to multiple
contact attempts or if all contacted study authors indi-
cate that they no longer have access to the data.
Initial data check
The initial data check will be used to ensure that data
received is from the correct trial and is in satisfactory
condition to be included in the meta-analysis. Data
received will be examined to see that it matches data
reported in the published papers. The descriptive statis-
tics from the paper including sample sizes, frequencies
of demographic variables, clinical diagnoses and means
of depression or anxiety symptom scales will be calcu-
lated and compared with the published papers wherever
possible. Clarification from authors will be sought when
discrepancies arise. If clarification is not available, and
the differences are deemed small and judged by three
researchers to not have implications for the overall
results of the study, the study will be included in the IPD
meta-analysis and a sensitivity analysis removing this
study will be conducted to ensure inclusion of this study
does not affect the results. Studies will be included when
they share the necessary data, missing data are not exces-
sive (relative to what is reported in the paper) and there
is consensus that study data are accurate.
Database creation
The database will be created in SPSS. Coding for the
database will be finalised when all data have been
received from the study authors. When a study has
coding that differs greatly from the other studies, two
researchers will arrive at a group consensus on the
recoding and clarification from the study authors will be
sought when necessary. A third member of the research
team will be consulted when discrepancies arise.
Aggregation
After the initial data checks have been completed, a
copy of each trial’s raw data will be recoded into a separ-
ate database that corresponds with the IPD meta-analysis
variables and will be recoded to match the coding of the
IPD database. SPSS will then be used to aggregate the
individual databases into one large IPD database, struc-
tured by study and individual patient ID. After the data
have been concatenated, the large IPD database of all
studies will again be checked for accuracy.




A conventional meta-analysis, using data from the pub-
lished papers, will be conducted in order to compare
the outcomes of studies that have contributed data to
the IPD meta-analysis with those studies that did not
contribute data. The goal of this analysis is to establish if
there are any significant differences in depression out-
comes, risk of bias and other study characteristics that
might bias the IPD meta-analysis. Effect sizes indicating
the differences between combination therapy and com-
parison treatments at post-treatment will be calculated
from data reported in the published paper by subtract-
ing the average post-treatment depression score of the
comparison treatment group from the combination
treatment group and dividing by the pooled SD. If
studies use dichotomous outcomes without reporting
means and SDs of the continuous depression scores, the
effect size calculations for dichotomous variables out-
lined by Borenstein et al39 will be used. These effect sizes
will then be compared in the Comprehensive
Meta-Analysis (CMA) software (V.3.0) using the
random-effects model because some heterogeneity
between studies is to be expected.
In addition, CMA software will be used to perform a
standard χ2 test to examine the amount of variation
across studies that is due to heterogeneity. The I2, which
expresses the amount of heterogeneity in percentages,
will be analysed and low (25%), medium (50%) or high
(75%) levels of heterogeneity will be reported.40 The
95% CI around I2 will be calculated using the heterogi
module in STATA. If high heterogeneity is found in the
point estimate or CI, further subgroup and metaregres-
sion analyses will be provided to explore possible causes
of heterogeneity. Small sample bias will be assessed by
visually examining the funnel plot and by using Duval
and Tweedie’s trim and fill procedure which provides an
estimated effect size after taking into account bias
related to including studies with small samples.41
Metaregression analyses will be run in CMA in order
to examine differences in outcome between studies that
contributed data and those that did not. The standar-
dised effect sizes will be the dependent variable and a
variable indicating whether data has or has not been
shared by the authors, and other study characteristics
such as bias score, type of recruitment and other
characteristics of the interventions will be entered as the
independent variables.
IPD meta-analysis
Primary depression outcome scales and time points in
each trial will be selected based on information from
the published papers and study authors. When different
primary outcome depression measures have been used
across the studies, we will convert the depression scores
into standardised z scores (by subtracting means from
the individual patient score and dividing by the SD
within each study and each measure separately) in order
to retain continuous scores of depression. However, con-
tinuous depression scores will also be converted into
response rates per individuals. The universal definition
of response is a 50% reduction of scores at post-
treatment, thus allowing this outcome to be compared
across studies and varying depression outcome
measures.
Missing outcome depression scores will be imputed in
STATA using valid predictor variables such as individual
clinical and demographic characteristics. A one-step IPD
meta-analysis approach will be used because it yields less
biased estimates and has better performance in terms of
power than a two-step approach in which a treatment ×
moderator interaction is estimated within each trial fol-
lowed by a standard inverse variance meta-analysis.42 43
The aggregated IPD will be examined using multilevel
regressions, clustering on the individual study level to
take into account any heterogeneity between studies.
These multilevel regressions will be used to examine the
effects of certain demographic and clinical predictors
and moderators on depression outcomes between com-
bination therapy and comparison groups.
In order to examine which patients with what individ-
ual characteristics respond better to combined treatment
or pharmacotherapy, psychotherapy (with or without pill
placebo) or pill placebo, clinical and demographic vari-
ables will also be collected. Clinical characteristics such
as baseline depression severity as measured by continu-
ous depression measures, comorbid diagnoses, chron-
icity of depression and demographic variables that are
commonly studied such as age, gender, employment and
marital status, are of particular interest in this study.
Moderator variables will be included in analysis if they
are represented in a sufficient number of trials.
Moderators found to be significant will be further
assessed with subgroup analyses that standardise effect
sizes. Effect sizes of standardised mean difference
(SMD)=0.24 or above are considered to be clinically
relevant.44
Sensitivity analysis
Several sensitivity analyses will be included to examine
the robustness of the IPD meta-analytic findings. It may
be the case that most studies will include an identical or
equivalent depression measurement as an outcome vari-
able. If this is the case, then sensitivity analysis using the
most used depression measure will be conducted in
order to compare analysis in these outcomes with the
z-score outcomes. If a sufficient number of trials incorp-
orate HAM-D-17 scores, then a dichotomous variable
indicating remission, defined as a HAM-D-17 score of
≤7, will be calculated and analysed as an outcome.
For comparison, similar multilevel models will be
employed using only the sample of participants who
completed the post-treatment outcome measure. In
addition, a third model will be examined that will
include individual patient characteristics as control
variables.
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Sensitivity analysis using individual types of psychother-
apy alone will be conducted when there are at least four
studies using a particular psychotherapy. This analysis
will explore whether moderators are specific to certain
types of psychotherapies. The same will be done with
respect to placebo combinations. Other sensitivity ana-
lyses may be necessary and will be determined after all
data have been collected and examined.
DISCUSSION
IPD meta-analysis techniques offer the ability to better
aggregate and analyse predictors and moderators of
depression outcome among treatments than conven-
tional meta-analysis. Using these models should allow
for a better understanding of the effects of patient-level
characteristics on depression outcomes than would arise
from conventional meta-analysis. Conventional
meta-analyses rely on aggregating subgroup analyses
reported similarly across all trial RCTs, which rarely
occurs. In addition, IPD meta-analysis offers greater stat-
istical power and precision with which to analyse predic-
tors, moderators and differences between outcomes
than can individual RCTs, as single trials often are
underpowered and thus not able to ascertain statistically
significant moderators. This approach also allows
researchers to standardise analytical methods across all
studies, for instance where some studies may have previ-
ously reported only remission rates and others mean
depression change over time. These can now be con-
verted from one type of measurement to the other for
optimal comparisons.45
IPD meta-analysis techniques also present several chal-
lenges. First, although they offer significant power to
examine moderators of treatment outcome, they must
rely on variables previously defined by individual studies.
This limits the analysis to exploring moderators that
have been collected, are available and are able to be
combined across studies. Thus, not all variables of inter-
est can be included. In addition, while recoding vari-
ables to be more similar to one another is necessary for
the analysis, it is possible that some important details
about these variables are omitted from the analysis.
Expected barriers to accessing data, such as not finding
an optimal method to contact authors or an author’s
lack of access to data may introduce some bias into the
IPD meta-analysis. However, this will be thoroughly
examined and addressed by additionally using conven-
tional meta-analysis techniques. Other sources of bias,
such as the inability to identify unpublished trials using
standard searching methods, may also be present.
Unpublished trials in psychotherapy research are diffi-
cult to identify without the labour-intensive task of exam-
ining records from institutional review boards across all
countries, and thus unpublished trial data will likely not
be included in this meta-analysis. This may lead to some
publication bias and results will need to be interpreted
accordingly.
The aforementioned benefits of using IPD meta-analysis
techniques greatly outweigh the challenges of using this
intensive method. IPD methods allow for a thorough
examination of predictors or moderators of treatment out-
comes that explain differential treatment effects, in this
case between combination treatment and various mono-
therapies or psychotherapy plus pill placebo for depres-
sion. Combination treatment for depression has been
proven effective, but it is unclear whether all patients
respond to this treatment similarly, or whether some
patients benefit more from a certain monotherapy.
Previous RCTs have not had sufficient power to thoroughly
examine moderators. Thus, although we know depression
treatments are equally effective, we do not know whether
certain kinds of patients (eg, those who are older or more
severe patients) will respond better to a specific type of
treatment than another. Knowing which types of patients
benefit more from combined treatment than monother-
apy can ensure that patients get the optimal treatment and
relieve clinicians of the burden to choose the best treat-
ment option for a given patient with very little information
to inform that decision. This project aims to contribute
this knowledge of which patients respond best to which
treatments, to clinicians and researchers in the field of
depression treatment.
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